JP2017526361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526361A5 JP2017526361A5 JP2017511182A JP2017511182A JP2017526361A5 JP 2017526361 A5 JP2017526361 A5 JP 2017526361A5 JP 2017511182 A JP2017511182 A JP 2017511182A JP 2017511182 A JP2017511182 A JP 2017511182A JP 2017526361 A5 JP2017526361 A5 JP 2017526361A5
- Authority
- JP
- Japan
- Prior art keywords
- signaling
- domain
- binding domain
- car
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000011664 signaling Effects 0.000 claims description 59
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 46
- 108020003175 receptors Proteins 0.000 claims description 34
- 102000005962 receptors Human genes 0.000 claims description 34
- 150000007523 nucleic acids Chemical group 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 210000000822 natural killer cell Anatomy 0.000 claims description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000002588 toxic effect Effects 0.000 claims description 8
- 238000012544 monitoring process Methods 0.000 claims description 6
- 108010021152 pepBs1-Ac peptide Proteins 0.000 claims description 6
- 206010061818 Disease progression Diseases 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- 230000005750 disease progression Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102000009661 Repressor Proteins Human genes 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 238000006471 dimerization reaction Methods 0.000 claims description 2
- 229960003722 doxycycline Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000004068 intracellular signaling Effects 0.000 claims description 2
- 229960004023 minocycline Drugs 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 8
- 230000002411 adverse Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1415347.2 | 2014-08-29 | ||
| GBGB1415347.2A GB201415347D0 (en) | 2014-08-29 | 2014-08-29 | Signalling system |
| PCT/GB2015/052494 WO2016030691A1 (en) | 2014-08-29 | 2015-08-28 | Signalling system |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526361A JP2017526361A (ja) | 2017-09-14 |
| JP2017526361A5 true JP2017526361A5 (2) | 2018-08-09 |
| JP6614619B2 JP6614619B2 (ja) | 2019-12-04 |
Family
ID=51752358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511182A Active JP6614619B2 (ja) | 2014-08-29 | 2015-08-28 | シグナル伝達系 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10654927B2 (2) |
| EP (2) | EP3981417A1 (2) |
| JP (1) | JP6614619B2 (2) |
| KR (1) | KR102222615B1 (2) |
| CN (1) | CN106573989B (2) |
| AU (1) | AU2015308243B2 (2) |
| BR (1) | BR112017003906A2 (2) |
| CA (1) | CA2955668A1 (2) |
| CL (1) | CL2017000438A1 (2) |
| ES (1) | ES2910008T3 (2) |
| GB (1) | GB201415347D0 (2) |
| IL (1) | IL250101B (2) |
| MX (1) | MX376613B (2) |
| NZ (1) | NZ728674A (2) |
| RU (1) | RU2731638C2 (2) |
| SG (1) | SG11201700171VA (2) |
| WO (1) | WO2016030691A1 (2) |
| ZA (1) | ZA201700466B (2) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2948544A4 (en) | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
| CN113354744A (zh) | 2013-12-20 | 2021-09-07 | 弗雷德哈钦森癌症研究中心 | 带标签的嵌合效应分子及其受体 |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| US20230027993A1 (en) | 2014-03-05 | 2023-01-26 | Autolus Limited | Methods |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| GB201501936D0 (en) | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| GB201504840D0 (en) | 2015-03-23 | 2015-05-06 | Ucl Business Plc | Chimeric antigen receptor |
| EP3288570A4 (en) * | 2015-04-29 | 2018-11-21 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
| CN107995913B (zh) | 2015-05-18 | 2022-02-11 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| GB201602571D0 (en) * | 2016-02-12 | 2016-03-30 | Autolus Ltd | Signalling system |
| GB201602563D0 (en) | 2016-02-12 | 2016-03-30 | Autolus Ltd | Signalling system |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| GB201610515D0 (en) * | 2016-06-16 | 2016-08-03 | Autolus Ltd | Cell |
| EP3472318B1 (en) * | 2016-07-08 | 2023-09-06 | Exuma Biotech Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CA3036745A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| JP2019535262A (ja) | 2016-11-11 | 2019-12-12 | オートラス リミテッド | キメラ抗原受容体 |
| US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| GB201621891D0 (en) * | 2016-12-21 | 2017-02-01 | Autolus Ltd | Transcription system |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| KR102660336B1 (ko) | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
| JP7132249B2 (ja) * | 2017-05-15 | 2022-09-06 | オートラス リミテッド | キメラ抗原受容体（ｃａｒ）を含む細胞 |
| GB201709203D0 (en) | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
| GB201709508D0 (en) * | 2017-06-15 | 2017-08-02 | Autolus Ltd | Chimeric antigen receptor |
| WO2019025800A1 (en) * | 2017-08-02 | 2019-02-07 | Autolus Limited | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE |
| CN107475276A (zh) * | 2017-09-05 | 2017-12-15 | 深圳大学 | 嵌合抗原受体及其表达基因、四环素调节的嵌合抗原受体修饰的t细胞及其应用 |
| GB201717524D0 (en) | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| CN112055717B (zh) | 2018-04-02 | 2024-04-26 | 新加坡国立大学 | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 |
| GB201805918D0 (en) * | 2018-04-10 | 2018-05-23 | Autolus Ltd | Cell |
| WO2019197676A1 (en) | 2018-04-13 | 2019-10-17 | Ludwig Institute For Cancer Research Ltd | Heterodimeric inactivatable chimeric antigen receptors |
| GB201807693D0 (en) | 2018-05-11 | 2018-06-27 | Autolus Ltd | Cell |
| AU2019269118B2 (en) | 2018-05-15 | 2025-02-27 | Autolus Limited | Chimeric antigen receptor |
| GB201813178D0 (en) | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| EP3847197A1 (en) * | 2018-09-05 | 2021-07-14 | Poseida Therapeutics, Inc. | Allogeneic cell compositions and methods of use |
| PL3856775T3 (pl) | 2018-09-27 | 2025-06-09 | Autolus Limited | Chimeryczny receptor antygenowy |
| GB201816839D0 (en) * | 2018-10-16 | 2018-11-28 | Glaxosmithkline Ip Dev Ltd | Novel control switch |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| WO2020183131A1 (en) | 2019-03-08 | 2020-09-17 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| GB201906202D0 (en) | 2019-05-02 | 2019-06-19 | Autolus Ltd | Cell |
| US20220257757A1 (en) | 2019-07-16 | 2022-08-18 | Autolus Limited | Method for preconditioning a subject who is about to receive a t-cell therapy |
| GB201910185D0 (en) | 2019-07-16 | 2019-08-28 | Autolus Ltd | Method |
| GB201913258D0 (en) | 2019-09-13 | 2019-10-30 | Autolus Ltd | Antigen-binding domain |
| GB201919017D0 (en) | 2019-12-20 | 2020-02-05 | Autolus Ltd | Cell |
| GB201919019D0 (en) | 2019-12-20 | 2020-02-05 | Autolus Ltd | Antigen-binding domain |
| GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| WO2021205175A1 (en) | 2020-04-09 | 2021-10-14 | Autolus Limited | Molecule |
| GB202101491D0 (en) | 2021-02-03 | 2021-03-17 | Autolus Ltd | Molecule |
| GB202007044D0 (en) | 2020-05-13 | 2020-06-24 | Autolus Ltd | Method |
| GB202017343D0 (en) | 2020-11-02 | 2020-12-16 | Autolus Ltd | Cell |
| GB202104030D0 (en) | 2021-03-23 | 2021-05-05 | Autolus Ltd | Signalling system |
| GB202115329D0 (en) | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
| GB202209920D0 (en) | 2022-07-06 | 2022-08-17 | Autolus Ltd | Cell |
| GB202219568D0 (en) | 2022-12-22 | 2023-02-08 | Autolus Ltd | Chimeric antigen receptor |
| GB202312009D0 (en) | 2023-08-04 | 2023-09-20 | Autolus Ltd | Methods and cell compositions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8551715B2 (en) | 2010-02-12 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for identifying and isolating cells expressing a polypeptide |
| EP4303232A3 (en) * | 2013-02-15 | 2024-04-17 | The Regents of The University of California | Chimeric antigen receptor and methods of use thereof |
| PL3546572T3 (pl) | 2013-05-13 | 2024-07-22 | Cellectis | Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania |
| US20160296562A1 (en) * | 2013-11-21 | 2016-10-13 | Ucl Business Plc | Cell |
| US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| US20170081411A1 (en) | 2014-03-15 | 2017-03-23 | Novartis Ag | Regulatable chimeric antigen receptor |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| US9791929B2 (en) * | 2014-10-31 | 2017-10-17 | Elwha Llc | Tactile control system |
| KR102376244B1 (ko) * | 2014-12-24 | 2022-03-21 | 오토러스 리미티드 | 세포 |
| GB201501936D0 (en) | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| GB201504840D0 (en) | 2015-03-23 | 2015-05-06 | Ucl Business Plc | Chimeric antigen receptor |
| WO2017123559A2 (en) * | 2016-01-11 | 2017-07-20 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric proteins and methods of regulating gene expression |
| GB201602571D0 (en) | 2016-02-12 | 2016-03-30 | Autolus Ltd | Signalling system |
| GB201602563D0 (en) | 2016-02-12 | 2016-03-30 | Autolus Ltd | Signalling system |
| GB201610515D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Cell |
-
2014
- 2014-08-29 GB GBGB1415347.2A patent/GB201415347D0/en not_active Ceased
-
2015
- 2015-08-28 WO PCT/GB2015/052494 patent/WO2016030691A1/en not_active Ceased
- 2015-08-28 SG SG11201700171VA patent/SG11201700171VA/en unknown
- 2015-08-28 CN CN201580045056.1A patent/CN106573989B/zh active Active
- 2015-08-28 CA CA2955668A patent/CA2955668A1/en not_active Abandoned
- 2015-08-28 KR KR1020177007191A patent/KR102222615B1/ko not_active Expired - Fee Related
- 2015-08-28 US US15/506,383 patent/US10654927B2/en active Active
- 2015-08-28 ES ES15757558T patent/ES2910008T3/es active Active
- 2015-08-28 BR BR112017003906-0A patent/BR112017003906A2/pt not_active IP Right Cessation
- 2015-08-28 RU RU2017105515A patent/RU2731638C2/ru active
- 2015-08-28 AU AU2015308243A patent/AU2015308243B2/en not_active Ceased
- 2015-08-28 NZ NZ728674A patent/NZ728674A/en not_active IP Right Cessation
- 2015-08-28 MX MX2017000616A patent/MX376613B/es active IP Right Grant
- 2015-08-28 EP EP21193028.4A patent/EP3981417A1/en not_active Withdrawn
- 2015-08-28 EP EP15757558.0A patent/EP3185875B1/en active Active
- 2015-08-28 JP JP2017511182A patent/JP6614619B2/ja active Active
-
2017
- 2017-01-15 IL IL250101A patent/IL250101B/en active IP Right Grant
- 2017-01-19 ZA ZA2017/00466A patent/ZA201700466B/en unknown
- 2017-02-23 CL CL2017000438A patent/CL2017000438A1/es unknown
-
2020
- 2020-04-14 US US16/848,717 patent/US20210032332A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526361A5 (2) | ||
| Kamiya et al. | Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells | |
| RU2017105515A (ru) | Сигнальная система | |
| JP7068459B2 (ja) | Ｎｙｅｓｏ ｔｃｒ | |
| Zhao et al. | Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential | |
| Dargel et al. | T cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells in vitro and in mice | |
| Jamieson et al. | The role of the NKG2D immunoreceptor in immune cell activation and natural killing | |
| JP2023518049A (ja) | 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体 | |
| Zhang et al. | Retargeting NK‐92 for anti‐melanoma activity by a TCR‐like single‐domain antibody | |
| JP2019530431A5 (2) | ||
| RU2016124278A (ru) | Клетка | |
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| BR112021007626A2 (pt) | Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d) | |
| KR20240063204A (ko) | Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법 | |
| JP2019535262A5 (2) | ||
| IL268620B2 (en) | Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment | |
| JP2016520074A5 (2) | ||
| RS65343B1 (sr) | Ćelija | |
| JP2021503006A5 (2) | ||
| WO2017130223A3 (en) | A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof | |
| JP2017513478A5 (2) | ||
| JP2019506841A5 (2) | ||
| JP2021511041A5 (2) | ||
| JP2020512973A5 (2) | ||
| JP2020501512A5 (2) |